个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li Ning[1] * ; Zhu Jianqing[2] * ; Yin Rutie[3] * ; Wang Jing[4] ; Pan Lingya[5] ; Kong Beihua[6] ; Zheng Hong[7] ; Liu Jihong[8] ; Wu Xiaohua[9] ; Wang Li[10] ; Huang Yi[11] ; Wang Ke[12] ; Zou Dongling[13] ; Zhao Hongqin[14] ; Wang Chunyan[15] ; Lu Weiguo[16] ; Lin An[17] ; Lou Ge[18] ; Li Guiling[19] ; Qu Pengpeng[20] ; Yang Hongying[21] ; Zhang Yu[22] ; Cai Hongbing[23] ; Pan Yueyin[24] ; Hao Min[25] ; Liu Ziling[26] ; Cui Heng[27] ; Yang Yingjie[28] ; Yao Shuzhong[29] ; Zhen Xiaoa[30] ; Hang Wenzhao[31] ; Hou Jianmei[31] ; Wang Juan[31] ; Wu Lingying[1] ;
机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. [3]West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China. [4]Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [5]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [6]Qilu Hospital of Shandong University, Jinan, China. [7]Peking University Cancer Hospital and Institute, Beijing, China. [8]Sun Yat-sen University Cancer Center, Guangzhou, China. [9]Fudan University Shanghai Cancer Center, Shanghai, China. [10]Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China. [11]Hubei Cancer Hospital (Affiliated Cancer Hospital of Tongji Medical College, Huazhong University of Science and Technology), Wuhan, China. [12]Tianjin Medical University Cancer Institute & Hospital, Tianjin, China. [13]Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Chongqing, China. [14]The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. [15]Cancer Hospital of China Medical University (Liaoning Cancer Hospital & Institute), Shenyang, China. [16]Women's Hospital School of Medicine Zhejiang University, Hangzhou, China. [17]Cancer Hospital of Fujian Medical University (Fujian Cancer Hospital), Fuzhou, China. [18]Harbin Medical University Cancer Hospital, Harbin, China. [19]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [20]Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China. [21]The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, China. [22]Xiangya Hospital of Central South University, Changsha, China. [23]Zhongnan Hospital of Wuhan University, Wuhan, China. [24]Anhui Provincial Hospital (The First Affiliated Hospital of USTC), Hefei, China. [25]Second Hospital of Shanxi Medical University, Taiyuan, China. [26]The First Hospital of Jilin University, The First Hospital of Jilin University, Changchun, China. [27]Peking University People's Hospital, Beijing, China. [28]The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China. [29]The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. [30]Zai Lab (US) LLC, Boston, Massachusetts. [31]Zai Lab (Shanghai) Co, Ltd, Shanghai, China.
出处：
DOI： 10.1001/jamaoncol.2023.2283
ISSN：

摘要：
The efficacy of niraparib maintenance therapy with an individualized starting dose (ISD) warrants further investigation in a broad population with newly diagnosed advanced ovarian cancer (aOC), including patients without postoperative residual disease.To evaluate the efficacy and safety of niraparib with an ISD in a broad population with newly diagnosed aOC (R0 resection permitted).This multicenter, randomized, double-blind, placebo-controlled, phase 3 study was conducted in China and enrolled 384 patients with newly diagnosed aOC who received primary or interval debulking surgery and responded to treatment with first-line platinum-based chemotherapy. By data cutoff (September 30, 2021), median follow-up for progression-free survival (PFS) was 27.5 (IQR, 24.7-30.4) months.Patients were randomized 2:1 to receive niraparib or placebo with ISD (200 mg/d for those with a body weight of <77 kg and/or platelet count of <150 ×103/μL [to convert to ×109/μL, multiply by 1] at baseline; 300 mg/d otherwise) stratified by germline BRCA variant status, tumor homologous recombination deficiency status, neoadjuvant chemotherapy, and response to first-line platinum-based chemotherapy.The primary end point was blinded, independent central review-assessed PFS in the intention-to-treat population.A total of 384 patients were randomized (255 niraparib [66.4%]; median [range] age, 53 [32-77] years; 129 placebo [33.6%]; median [range] age, 54 [33-77] years), and 375 (247 niraparib [65.9%], 128 placebo [34.1%]) received treatment at a dose of 200 mg per day. Median PFS with niraparib vs placebo was 24.8 vs 8.3 months (hazard ratio [HR], 0.45; 95% CI, 0.34-0.60; P < .001) in the intention-to-treat population; not reached vs 10.8 months (HR, 0.40; 95% CI, 0.23-0.68) and 19.3 vs 8.3 months (HR, 0.48; 95% CI, 0.34-0.67) in patients with and without germline BRCA variants, respectively; not reached vs 11.0 months (HR, 0.48; 95% CI, 0.34-0.68) and 16.6 vs 5.5 months (HR, 0.41; 95% CI, 0.22-0.75) in homologous recombination deficient and proficient patients, respectively; and 24.8 vs 8.3 months (HR, 0.44; 95% CI, 0.32-0.61) and 16.5 vs 8.3 months (HR, 0.27; 95% CI, 0.10-0.72) in those with optimal and suboptimal debulking, respectively. Similar proportions of niraparib-treated and placebo-treated patients (6.7% vs 5.4%) discontinued treatment due to treatment-emergent adverse events.This randomized clinical trial found that niraparib maintenance therapy prolonged PFS in patients with newly diagnosed aOC regardless of postoperative residual disease or biomarker status. The ISD was effective and safe in the first-line maintenance setting.ClinicalTrials.gov Identifier: NCT03709316.

基金：
This study was funded by Zai Lab (Shanghai) Co, Ltd, and partially supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development in 2020 (China; grant 2020ZX09101-014).
语种：
外文
高被引：
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Li Ning,Zhu Jianqing,Yin Rutie,et al.Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial[J].JAMA ONCOLOGY.2023,9(9):1230-1237.doi:10.1001/jamaoncol.2023.2283.
APA：
Li Ning,Zhu Jianqing,Yin Rutie,Wang Jing,Pan Lingya...&Wu Lingying.(2023).Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA ONCOLOGY,9,(9)
MLA：
Li Ning,et al."Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial".JAMA ONCOLOGY 9..9(2023):1230-1237

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号